Sponsors › Mayo Clinic

Mayo Clinic

Every GLP‑1 and incretin trial, approval and scheduled result we hold for Mayo Clinic, drawn from ClinicalTrials.gov and Drugs@FDA.

Mayo Clinic is an academic or hospital sponsor, not a drug company with 14 trials in the incretin class on file here, across 4 molecules. The programme is split between 3 early-stage trials and 11 in phase 3 or later. The next scheduled result is 2026-12-31.

Molecules

exenatide · liraglutide · semaglutide · tirzepatide

Trials on file

14

Active trials

7

Results scheduled

2

Approved FDA submissions

0

Results due

Trials on file

All 14 incretin trials recorded for this sponsor, active first.